Two Inhibitex Inc. shareholders sued claiming Bristol-Myers Squibb Co.’s $2.5 billion buyout offer undervalues the drugmaker. Shareholders Charles C. Osborne Jr. and Hortensia Osborne are asking a judge to bar the proposed transaction. The deal will prevent Inhibitex shareholders from benefiting from the company’s long-term prospects, according to the complaint filed yesterday in Delaware Chancery Court.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”